VarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from the Netherlands Enterprise Agency (RVO.nl) to develop a modified blood coagulation factor X to prevent severe bleeding in haemophilia patients.
The EMA’s CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday.
German and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.
Agribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.
Roche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.
Selvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners.
Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.
A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.
Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.
For two days, innovation in synthetic and bio-based fine chemicals will be in the focus of experts who meet at Chemspec Europe in Cologne (20-21 June, 2018, Koelnmesse).